Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how many people have been treated with (a) Ronapreve, (b) Sotrovimab or (c) molnupiravir for covid-19 in each week since the start of December 2021.

Ronapreve is available to treat patients in hospital who have confirmed COVID-19 and have either been hospitalised for the management of symptoms or are at high-risk of progression to severe illness. To 5 January 2022, 78 patients had been treated through the COVID Medicines Delivery Units (CMDUs).

The deployment of Sotrovimab began on 20 December 2021. To 5 January 2022, 1,961 patients had been treated through the CMDUs. The deployment of molnupiravir began on 16 December 2021. To 5 January 2022, 2,883 patients had been treated through the CMDUs. To 10 January 2022, 2,875 people enrolled on the PANORAMIC national study which has a molnupiravir treatment ratio of 1:1.